2 May 2018 - - Indianapolis, Indiana-based global pharmaceuticals specialist Eli Lilly and Company (NYSE: LLY) has selected Leena Gandhi, M.D., Ph.D. to lead immuno-oncology medical development at Lilly Oncology, the company said.
Gandhi is currently the director of Thoracic Medical Oncology and an associate professor of medicine at the New York University (NYU) School of Medicine. She graduated from the NYU School of Medicine and completed her fellowship at Dana-Farber Cancer Institute (DFCI) where she worked in the Early Drug Development Center and in the Thoracic Oncology Program as the head of clinical trials until 2016, at which point she joined NYU Perlmutter Cancer Center as the director of Thoracic Medical Oncology.
Gandhi has worked on Phase 1, 2 and 3 trials of novel targeted therapies and immunotherapies in lung cancer, with a focus on evaluating potential biomarkers of response.
She has been a lead investigator in clinical trials that helped define the use of PD-L1 as a biomarker of response to PD-1 inhibition in non-small cell lung cancer.
She most recently served as the lead investigator on the KEYNOTE-189 study that demonstrated an improved survival rate with the addition of pembrolizumab to pemetrexed and platinum chemotherapy for patients with recurrent lung cancer.
Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.